Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study

Authors: Littell, Ramey | Annals Of Oncology : Official Journal Of The European Society For Medical Oncology | October 18, 2025 | PubMed abstract

Explore all publications

Back To Top